Skip to content
lifestyle.longislandreport.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Climb Bio, Inc.
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
September 3, 2026
Climb Bio to Present at Upcoming Investor Conferences
September 2, 2026
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
June 11, 2026
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
June 5, 2026
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
May 26, 2026
Climb Bio, Inc. Announces $110.0 Million Private Placement
April 28, 2026
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
April 8, 2026
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
April 7, 2026
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 5, 2026
1
2
Next Page
→